ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SVRA
MLTX (32) RIGL (75) ORIC (30) CTY (50) ⌘ Pro Terminal →

Savara Inc. (SVRA) — RQD Stock Rating Cockpit

$4.73 -1.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.71

Savara Inc. (SVRA) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $990.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SVRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SVRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Savara Inc. (NASDAQ: SVRA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $4.73 (-1.87% 1D, market cap $990.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SVRA ranks #623 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SVRA compare to MLTX and RIGL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SVRA carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MLTX (MoonLake Immunotherapeutics (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $1.00B) and RIGL (Rigel Pharmaceuticals Inc.) posts a B grade (75/100 RQD, P/E N/A, ROIC 28.2%, cap $958.5M). Among the 5-stock peer group, SVRA leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SVRA?
▼

Per SVRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001160308), Savara Inc. generated $345.9M in revenue (+19.7% YoY), -$118.8M in net income, and -$101.1M in free cash flow against $253.4M in total assets and $29.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.70 (-0.53%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (6)SEC (10)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$7 Bull$4 Base$3 Bear
📬 FREE SVRA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SVRA)Realized 20D OHLCV Swing Band: ±12.3%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY SVRA SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 28% of 52W Range • RSI-14 at 49.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$4.78-0.4% Next Q
Q2 (-2Q)
39
Grade E$4.76+2.1% Next Q
Q3 (-1Q)
37
Grade E$4.86-2.7% Next Q
Current
34
Grade E$4.73-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SVRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SVRA currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.05) and Max Pain ($4.97) forces dealer call-delta covering toward $7.36.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SVRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SVRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
49.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE28% OF RANGE
L: $4$4.73H: $7
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 9 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on SVRA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -9.94% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (28)

9/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like SVRA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SVRA)

  • ✓Walkthrough of SVRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SVRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.75%▼ DESCENDING CHANNEL
2026-11-03O $4.95H $4.95L $4.73C $4.73VOL 1.41M
RES: $5.10SUP: $3.99SMA50: $5.05SMA200: $5.38
$6.63$5.96$5.28$4.60$3.92RES $5.10SUP $3.99$4.732026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SVRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SVRA Butterfly Map → + Track SVRA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +19.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SVRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SVRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SVRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SVRA)

Health Care Rank #623 of 1015 ⚔️ MLTX vs SVRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SVRA vs. MLTX, RIGL, ORIC, CTY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Savara Inc. (SVRA) ranks #623 by composite RQD confidence (34/100, grade E) and #357 by equity capitalization ($990.3M). Within this direct 5-issuer industry benchmark cohort, SVRA leads on earnings valuation at N/A trailing P/E, while RIGL leads on capital efficiency and profitability with 28.2% ROIC and 93.3% gross margin. RIGL currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with SVRA at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SVRA ACTIVE
Savara Inc.
E 34/100 — — -35.0% -1.87% $990.3M Benchmark Subject
MLTX
MoonLake Immunotherapeutics (Class A)
E 32/100 — — -35.0% -2.63% $1.00B /mltx-vs-svra →
RIGL
Rigel Pharmaceuticals Inc.
B 75/100 — 93.3% 28.2% -1.52% $958.5M /rigl-vs-svra →
ORIC
Oric Pharmaceuticals Inc.
E 30/100 — — -33.4% -1.84% $957.8M /oric-vs-svra →
CTY
City Therapeutics Inc.
D 50/100 — — — +0.82% $1.04B /cty-vs-svra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001160308 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Savara Inc. (SVRA) reported GAAP revenue of $345.9M (+19.7% vs. FY2024 revenue of $288.9M , and +105.9% cumulative change since FY2023) , GAAP net income of -$118.8M, operating cash flow of -$101.0M, and free cash flow of -$101.1M (-13.4% YoY). On the balance sheet, SVRA closed FY2025 with $253.4M in total assets against $29.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $345.9M -$118.8M -$101.0M -$101.1M $253.4M $29.9M
FY2024 (FY) 2024-12-31 $288.9M -$95.9M -$89.1M -$89.1M $212.9M $26.6M
FY2023 (FY) 2023-12-31 $168.0M -$54.7M -$51.1M -$51.1M — —

3. SVRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SVRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Savara Inc. (NASDAQ: SVRA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $4.73 (-1.87% 1D, market cap $990.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SVRA ranks #623 in composite RQD confidence.

How does SVRA compare to MLTX and RIGL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SVRA carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MLTX (MoonLake Immunotherapeutics (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $1.00B) and RIGL (Rigel Pharmaceuticals Inc.) posts a B grade (75/100 RQD, P/E N/A, ROIC 28.2%, cap $958.5M). Among the 5-stock peer group, SVRA leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SVRA?

Per SVRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001160308), Savara Inc. generated $345.9M in revenue (+19.7% YoY), -$118.8M in net income, and -$101.1M in free cash flow against $253.4M in total assets and $29.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SVRA trading relative to its 50-day, 200-day, and 52-week technical levels?

SVRA last traded at $4.73 (-1.87% on volume of 1,777,728 shares), positioning the stock -6.34% below its 50-day simple moving average ($5.05) and -12.08% below its 200-day simple moving average ($5.38). Across its 52-week range of $3.86 to $7.01, SVRA sits at the 27.6% percentile with a 14-day RSI of 49.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.3% ($4.15 to $5.31).

Direct Sub-Reports: SVRA RQD Cockpit SVRA 12M Forecast SVRA Earnings & Move SVRA Dividends & DRIP SVRA Insiders & 13F SVRA Whale Options SVRA Profit Sankey SVRA News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

SVRA — Savara Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Savara Inc. (SVRA) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.73 (-1.87% 1D, market capitalization $990.3M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -9.94%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of 0.15x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Savara Inc. (SVRA) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It has a market capitalization of $1.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Savara Inc. (SVRA) reported $345.9M in annual revenue (up from $288.9M in FY2024, +19.7% YoY) and -$118.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($168.0M revenue, -$54.7M net income) through FY2025, SVRA scaled operating cash flow to -$101.0M and free cash flow to -$101.1M, backed by $253.4M in total assets against $29.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -9.94% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $3.86 – $7.01 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not establish upstream or downstream dependencies, sector correlations, or second-order bottlenecks. The only sector information available is the Health Care classification and Biotechnology: Pharmaceutical Preparations industry label, plus the Beta of 1.0.

  • Key Question #1: Can SVRA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $345.9M and free cash flow of -$101.1M, how will capital allocation balance growth reinvestment against $29.9M in total debt?
  • Key Question #3: How sensitive is SVRA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SVRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Savara Inc. (SVRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SVRA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SVRA Bull vs. Bear Conversation Board — What's Your Call at $4.73?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SVRA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SVRA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $5.78 (+19.9%)
📌 Pinned Debate

The Forensic Balance Sheet pillar scores 10/20 with a Debt/Equity of 0.15 and an Altman Z of 2.5, which is the strongest input in the r

Long SVRA at $4.82 targeting $5.78. The Forensic Balance Sheet pillar scores 10/20 with a Debt/Equity of 0.15 and an Altman Z of 2.5, which is the strongest input in the rating.. Institutional whale score is 6/20 and the risk/reward vs. the $3.86 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $4.15 (-13.9%)
Spot @ $4.82

Reported free cash flow was negative in every listed period, reaching -$101.1M in FY 2025, while ROIC is -35% and Insider Conviction sc

I respect the product at Savara Inc., but the stock at $4.82 is a different story. Reported free cash flow was negative in every listed period, reaching -$101.1M in FY 2025, while ROIC is -35% and Insider Conviction scores only 3/20.. FCF yield is -9.94% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%